The MTT/MTS in vitro cell proliferation assay is one of the most widely used assays for evaluating preliminary anticancer activity of both synthetic derivatives and natural products and natural product extracts. The highly reliable, colorimetric based assay is readily performed on a wide range of cell lines. This assay gives an indication of whole cell cytotoxicity; however, to determine the exact molecular target further assays need to be performed. Of these, kinase inhibition assays are also one of the most widespread enzyme inhibition screening assays performed. Kinases are enzymes that play a key role in a number of physiological processes and their inhibitors have been found to exhibit anticancer activity against various human cancer cell lines. Herein, we describe the methods for performing both in vitro MTT/MTS cytotoxicity and kinase enzyme inhibition assays. These are two of the most useful anticancer screening techniques available that are relatively economical and can be easily and routinely performed in the laboratory to characterize anticancer activity. Both assays are highly versatile and can be modified to test against targeted disease processes by using specific kinase enzymes or cell lines. 
Introduction
A goal of many natural product chemistry and organic synthesis laboratories is ultimately drug discovery. An important aspect of the drug development process is testing both natural products and synthesised compounds for bioactivities that are involved in targeted diseases processes. Cancer is a general term to define a number of diseases that are characterised by the uncontrolled proliferation of cells resulting from the disruption or dysfunction of regulatory signaling pathways that are normally under tight control (1) (2) . Cancer can spread rapidly and invade other tissues and organs and different cancers are recognized to have unique characteristics or markers
(3).
To assess for preliminary anticancer activity in terms of cell viability, the MTT and MTS in vitro cytotoxicity assays are considered two of the most economic, reliable and convenient methods. This is based on their ease of use, accuracy and rapid indication of toxicity (4) , as well as their sensitivity and specificity (5) . Both assays are in vitro whole cell toxicity assays that employ colorimetric methods for determining the number of viable cells based on mitochondrial dehydrogenase activity measurement and differ only in the reagent employed. In the MTT assay, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide is bioreduced by dehydrogenase inside living cells to form a coloured formazan dye, while in the MTS assay, a similar bioconversion takes places utilising 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt and an electron coupling reagent (phenazine ethosulfate) PES (Fig. 1) .
The MTT assay requires the addition of solubilising agents to dissolve the insoluble formazan product formed, while the MTS assay generates a water-soluble formazan product, thus simplifying the assay. The number of viable cells is measured through colorimetry and works on the principle that the mitochondrial dehydrogenase enzymes which produces NADH or NADHP, reduces the colourless tetrazolium salt into a coloured aqueous soluble formazan product by the mitochondrial activity of viable cells at 37°C (Fig. 1) . The quantity of the coloured product is directly proportional to the number of live cells in the culture since the MTT/MTS reagent can only be reduced to formazan by metabolically active cells.
[Insert Figure 1 near here]
This is a useful assay to characterise potential anticancer agents and can be performed routinely and easily in the laboratory without the need to forego intellectual property. The MTT and MTS assays assess for toxicity to the particular cell under investigation (not anticancer activity per se). Therefore, most researchers screen for cytotoxicity against either murine or human cancer cell lines, as well as against a normal cell line such as peripheral blood lymphocytes. A selectivity index of the compound for cancer cells over normal cells can then be determined. It is also advisable to confirm MTS/MTT results with qualitative observations under the microscope of the cell morphology both before and after the assay. This can often assist in identifying potential modes of actions and deciding which further assays should be performed such as caspase activation, assessing stage of cell cycle arrest and microtubule stabilisation or destabilisation (6) .
In addition to performing MTT or MTS assays against specific cell types, many researchers also submit their compounds to screening by the National Cancer Institute (NCI). The NCI offers a rapid in vitro primary anticancer drug screen to support cancer researchers worldwide (7) . The screen, which is performed at no cost to the researcher other than shipping of their sample, consists of a panel of 60 different human tumour cell lines from several cancer types including leukemia, melanoma and cancers of the lung, colon, brain, ovary, breast, prostate and kidney.
The NCI60 screen tests the degree of growth, inhibition or cytotoxicity of a compound against each cell line over a range of concentrations to generate a characteristic profile or fingerprint of cellular response (8) . A computer program (COMPARE) is used to assess the pattern of response across the cell lines, which can point towards a likely mechanism of action or identify compounds with unique modes of activity and/or selectivities for specific cell types. Operational details are provided by the NCI Developmental Therapeutics Program (DTP) and can be found at http://dtp.nci.nih.gov and for information regarding the submission of compounds for testing in the NCI screens see http://dtp.nci.nih.gov/docs/misc/common_files/submit_compounds.html (9) . Only pure compounds are screened in the assay and the supplier of the sample is required to provide the molecular structure of any compounds submitted, which are then reviewed and considered for testing.
The above assays are whole cell assays, however, often a researcher will want to determine activity against a specific molecular or cellular target in order to confirm the mechanism of action and to assess for selectivity towards different targets and any off-target effects. This can be achieved using in vitro inhibition assays against either purified enzymes or cell-free extracts enriched in the enzyme target of interest. One such anticancer screening method that can be easily and routinely performed in the laboratory in low-, medium-or high-throughput format is protein kinase inhibition (10) . After G protein-coupled receptors (GPCRs), protein kinases are the second most important anticancer drug target being pursued today.
Unlike MTS-type assays, which are cell based, these assays are based on detecting the degree to which the potential drug compound can inhibit an enzyme's activity. Most drugs used today demonstrate their bioactivity by acting as either receptor antagonists or as enzyme inhibitors. Enzymes are popular drug targets as they play a significant role in a number of disease processes and are susceptible to inhibition by small drug-like molecules (11) .
Protein kinases are an abundant group of enzymes in the human body with approximately 518 different protein kinases encoded in the human genome (12) .
Kinases catalyse the chemical transfer of a phosphate group from a high energy molecule such as adenine triphosphate (ATP) to a hydroxyl-containing substrate such as serine, threonine and tyrosine, and are divided into different families based on their selectivity for these amino acids.
As one of the most abundant groups of enzymes in the human body, protein kinases are important in almost every major pathway in eukaryotic cells. They play a central role in the regulation of cellular activities and in signal transduction in signal transmission pathways. Moreover, kinases have important roles in metabolism, cell growth, apoptosis, immune response, gene expression, oncogenesis, cell differentiation and proliferation, metabolism, DNA damage repair and cell motility (2) . As a result, the deregulation of kinases has been identified to be the main cause in an increasing list of diseases (13) . An estimated one-third of pharma drug discovery programs now focus on targeting cancer-related kinases with the aim of developing potent and selective inhibitors with lower side effects than treatments that traditionally focus on DNA and chromosome regulation (14) (15) (16) (17) . An example of a kinase inhibitor that has successfully proceeded onto the pharmaceutical market is Imitinib (Gleevec, Novartis) which is a tyrosine kinase inhibitor that has dramatically improved the prognosis for sufferers of chronic myeloid leukaemia after being the first small-molecule kinase inhibitor to be approved for human use (13) . (24) . Thus, it is becoming increasingly apparent that the ability to selectively inhibit PKA provides a new way of potentially modulating cancer, immune function, and memory disorders such as Alzheimer's disease, Parkinson's disease and schizophrenia (19, 21, 25) .
Herein, we describe methods for performing both the MTT/MTS cell proliferation cytotoxicity assay and for screening against the enzyme PKA. Both methods are widely used in our laboratory (6, (26) (27) .
Materials
Carry out all procedures at room temperature unless otherwise specified.
Protein kinase assay
This protocol is for the analysis of 14 samples per plate -each sample is run twice at 100 μg/mL and in triplicate. This gives six data points per % inhibition reading.
Alternatively, 14 samples can be run once at two different concentrations (100 μg/mL, 1 μg/mL) in triplicate. This will give three data points per % inhibition reading (adjust protocol accordingly). The volumes provided in this protocol are intended for a 96-well plate. The actual volumes used can be adjusted as needed. 
MTS assay
Plates containing compound dilutions should be discarded in cytotoxic waste bins. All pipette tips that came into contact with the test compounds should also be disposed of in cytotoxic waste bins 1. Sample preparation: Prepare a 4 mg/mL stock solution of sample in DMSO.
MTS reagent:
Should be stored at -20 ºC for long-term storage and protected from light. Reagent should be warmed up to room temperature before use in the assay. 12. UV spectrophotometer compatible for 96-well plate.
Methods
The kinase assay described here utilises the Kinase-Glo ® Luminsecent Kinase Assay Platform from Promega and is performed according to the manufacturer's instructions (28) with minor modifications as used in our laboratory. The method below is relevant to screening against PKA, however a wide range of kinases can be used in this assay including GSK-3β, PI3K, Src and MAPK (29, 28) . In theory, potentially any kinase could be used, provided the appropriate substrate is also utilised.
Kinase Assay
1. To wells A/F1-12 of a 96-well plate, add 5 μL of the 1 mg/mL stock solution of the test compounds, which will give a final concentration of 100 μg/mL sample in 2% DMSO ( Table 1) . To the positive control wells (G1-6) and the negative control wells (H1-6), add 5 μL of the 20% DMSO solution.
[Insert Table 1 around here] 2. To wells G/H7-12, add 5 μL of the internal standard (e.g. staurosporine). This will give a final concentration of 10 μM in each well per 50 μL reaction.
See Table 2 for a summary of the reagent volumes added to the 96-well plate. [Insert Table 2 around here]
MTS Assay
The MTS assay described here utilises Promega [Insert Figure 2 near here] 5 . Pipette 90 µL of media into wells B8-G8, B9-G9, B10-G10. These wells will form the sample background controls. 6 . Pipette 90 µL of cell solution into wells B2-G2, B3-G3, B4-G4. These wells will form the sample wells.
7.
Pipette 90 µL of cell solution into wells D5-D7. These wells will form the 2.5% DMSO controls.
8. Pipette 100 µL of cell solution into wells C5-C7. These wells will form the cell controls.
9. Incubate plates for 24 hours at 37 ºC with 5% carbon dioxide (CO 2) .
Day Two -Diluting Test Compounds:
Prepare a microtitre plate for serial dilutions of the test compounds as shown in Fig. 3 for each compound to be tested. Wells A3-G3 should all contain a final volume of 100 µL.
[Insert Figure 3 near here] 11. Adding serial dilutions of samples to cells: Using the plate of cells prepared on Day 1, pipette 10 µL of each sample dilution of the test compound in 25% DMSO (i.e. A3-F3, step 11) in triplicate into the 18 wells containing 90 µL of cell solution (i.e. 10 μL of the sample at 500 ug/mL in triplicate into wells B2-B4, 250 ug/mL sample into C2-C4 etc, down to the 15.5 µg/mL sample into G2-4). Repeat this step, by adding 10 µL of the serial dilutions of the sample in triplicate to the 18 wells containing 90 µL of media (e.g. wells B8-G8, B9-G9, B10-G10). The test compounds will now have a final concentration of 2.5% DMSO in all wells.
12. Pipette 10 µL of the 0 µg/mL in 25% DMSO (i.e. G3 from step 11) into the three remaining wells containing 90 µL cells (wells D5-D7). This will be the 2.5% DMSO control. 2. We found that a starting stock solution of 1 mg/mL of sample (diluted to 100 µg/mL in the assay) was appropriate to identify kinase inhibitory activity.
Samples can be tested at lower concentrations or over a range of different concentrations to determine IC 50 values.
3. We found that it is best to prepare the buffer solution fresh each time and to store the buffer at room temperature.
4. For kinases other than PKA, the optimum amount of kinase enzyme will need to be determined and the quantity of other reagents adjusted accordingly (28).
5. Kemptide (PKA Peptide Substrate) is a synthetic peptide substrate for PKA derived from the PKA phosphorylation site in liver pyruvate kinase.
6. This assay can be used to identify whether the kinase inhibitor is ATP competitive or non-competitive, by utilising various ratios of ATP (e.g. <10
μM ATP for ATP-competitive inhibitors and >100 μM for ATP noncompetitive inhibitors). In general, we found it is best to prepare ATP solutions fresh, while the ATP reagent itself should be stored in the freezer. 14. The most common assay detection methods are colorimetric or fluorescencebased. However, luminescent-based detection is particularly desirable for coloured products such as natural products, as coloured extracts and compounds can lead to false results when using absorbance as the end point.
Utilization of luminescence can be more beneficial for biological screening by identifying hits with a lower number of false positives (35 16. Longer incubation times of 48 -72 hours are also routinely employed in this assay.
17. The MTS reagent is light sensitive so this step should be performed with the lights off in the cytotoxic cabinet.
18. As this is a colorimetric assay, it should be kept in mind that both coloured compounds and natural product extracts may interfere with the absorbance reading, and appropriate background controls should always be performed. Preparation of microtitre plate for 1:2 serial dilutions. Add 100 µL of DMSO and 100 µL of the test compound (4 mg/mL in DMSO) to well A1. Next, add 100 µL of DMSO to wells B1 to G1. Then, 100 µL is transferred from A1 to B1; B1 to C1 and so forth until F1, where 100 µL is removed and discarded. G1 should contain just 100 μL of 100% DMSO. Next 50 µL of media is added to wells A2-G2 and A3-G3 and 50 µL transferred from A1 to A2 and then from A2 to A3 to give 100 µL of the sample at a concentration of 500 μg/mL in 25% DMSO in media. This is repeated for wells B2-B3, C2-C3, etc to give a series of 1:2 dilutions of the sample.
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